Diabetic nephropathy – complications and treatment

References

• International Diabetes FederationIDF Diabetes Atlas6th edBrussels, BelgiumInternational Diabetes Federation2013 Available from: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdfAccessed September 2, 2014
   Google Scholar
• Centers for Disease Control and PreventionNational diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United StatesAtlanta, GAUS Department of Health and Human Services2011 Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdfAccessed September 2, 2014
   Google Scholar
• TappRJShawJEZimmetPZAlbuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)Am J Kidney Dis200444579279815492944
   PubMed Web of Science ®Google Scholar
• ScottLJWarramJHHannaLSLaffelLMRyanLKrolewskiASA nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetesDiabetes200150122842284911723069
   PubMed Web of Science ®Google Scholar
• RossingPHougaardPParvingHHRisk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational studyDiabetes Care200225585986411978681
   PubMed Web of Science ®Google Scholar
• SatkoSGLangefeldCDDaeihaghPBowdenDWRichSSFreedmanBINephropathy in siblings of African Americans with overt type 2 diabetic nephropathyAm J Kidney Dis200240348949412200799
   PubMed Web of Science ®Google Scholar
• PettittDJSaadMFBennettPHNelsonRGKnowlerWCFamilial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitusDiabetologia19903374384432401399
   PubMed Web of Science ®Google Scholar
• SeaquistERGoetzFCRichSBarbosaJFamilial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathyN Engl J Med198932018116111652710189
   PubMed Web of Science ®Google Scholar
• YoungBAMaynardCBoykoEJRacial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veteransDiabetes Care20032682392239912882868
   PubMed Web of Science ®Google Scholar
• SmithSRSvetkeyLPDennisVWRacial differences in the incidence and progression of renal diseasesKidney Int19914058158221762285
   PubMed Web of Science ®Google Scholar
• GallMAHougaardPBorch-JohnsenKParvingHHRisk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational studyBMJ199731470837837889080995
   PubMed Web of Science ®Google Scholar
• MooyaartALValkEJvan EsLAGenetic associations in diabetic nephropathy: a meta-analysisDiabetologia201154354455321127830
   PubMed Web of Science ®Google Scholar
• DellameaBSPintoLCLeitaoCBSantosKGCananiLHEndothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysisBMC Med Genet201415924433471
   PubMed Web of Science ®Google Scholar
• LinZHuangGZhangJLinXAdiponectin gene polymorphisms and susceptibility to diabetic nephropathy: a meta-analysisRen Fail201436347848724344808
   PubMed Web of Science ®Google Scholar
• ZhouTBGuoXFYinSSAssociation of peroxisome proliferator-activated receptor γ Pro12Ala gene polymorphism with type 2 diabetic nephropathy risk in Caucasian populationJ Recept Signal Transduct Res201434318018424329532
   PubMed Web of Science ®Google Scholar
• MooyaartALGenetic associations in diabetic nephropathyClin Exp Nephrol201418219720024129556
   PubMed Web of Science ®Google Scholar
• MolitchMEDeFronzoRAFranzMJAmerican Diabetes AssociationNephropathy in diabetesDiabetes Care200427Suppl 1S79S8314693934
   PubMed Web of Science ®Google Scholar
• DrummondKMauerMThe early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetesDiabetes20025151580158711978659
   PubMed Web of Science ®Google Scholar
• BrunoGMerlettiFBiggeriAProgression to overt nephropathy in type 2 diabetes: the Casale Monferrato StudyDiabetes Care20032672150215512832328
   PubMed Web of Science ®Google Scholar
• JohnsonDWJonesGRMathewTHChronic kidney disease and measurement of albuminuria or proteinuria: a position statementMed J Aust20121974224225
   Web of Science ®Google Scholar
• American Diabetes AssociationStandards of Medical Care in Diabetes – 2014Diabetes Care201437Suppl 1S14S8024357209
   PubMed Web of Science ®Google Scholar
• MazzuccoGBertaniTFortunatoMDifferent patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsiesAm J Kidney Dis200239471372011920336
   PubMed Web of Science ®Google Scholar
• MakSKGwiEChanKWClinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitusNephrol Dial Transplant19971212258825919430856
   PubMed Web of Science ®Google Scholar
• SharmaSGBombackASRadhakrishnanJThe modern spectrum of renal biopsy findings in patients with diabetesClin J Am Soc Nephrol20138101718172423886566
   PubMed Web of Science ®Google Scholar
• PerkinsBAFicocielloLHRoshanBWarramJHKrolewskiASIn patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuriaKidney Int2010771576419847154
   PubMed Web of Science ®Google Scholar
• CaramoriMLFiorettoPMauerMLow glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesionsDiabetes20035241036104012663477
   PubMed Web of Science ®Google Scholar
• PerkinsBAFicocielloLHOstranderBEMicroalbuminuria and the risk for early progressive renal function decline in type 1 diabetesJ Am Soc Nephrol20071841353136117329575
   PubMed Web of Science ®Google Scholar
• ArgyropoulosCWangKMcClartySUrinary microRNA profiling in the nephropathy of type 1 diabetesPLoS One201381e5466223358711
   PubMed Web of Science ®Google Scholar
• DiStefanoJKTailaMAlvarezMLEmerging roles for miRNAs in the development, diagnosis, and treatment of diabetic nephropathyCurr Diab Rep201313458259123666892
   PubMed Web of Science ®Google Scholar
• GohdaTNiewczasMAFicocielloLHCirculating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetesJ Am Soc Nephrol201223351652422266664
   PubMed Web of Science ®Google Scholar
• NiewczasMAGohdaTSkupienJCirculating TNF receptors 1 and 2 predict ESRD in type 2 diabetesJ Am Soc Nephrol201223350751522266663
   PubMed Web of Science ®Google Scholar
• WeilEJLemleyKVMasonCCPodocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathyKidney Int20128291010101722718189
   PubMed Web of Science ®Google Scholar
• ToyodaMNajafianBKimYCaramoriMLMauerMPodocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathyDiabetes20075682155216017536064
   PubMed Web of Science ®Google Scholar
• HuangWGalloisYBoubyNGenetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouseProc Natl Acad Sci U S A20019823133301333411687636
   PubMed Web of Science ®Google Scholar
• RudbergSRasmussenLMBangstadHJOsterbyRInfluence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuriaDiabetes Care200023454454810857950
   PubMed Web of Science ®Google Scholar
• KanetsunaYTakahashiKNagataMDeficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred miceAm J Pathol200717051473148417456755
   PubMed Web of Science ®Google Scholar
• HanedaMArakiSTogawaMSugimotoTIsonoMKikkawaRMitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditionsDiabetes19974658478539133554
   PubMed Web of Science ®Google Scholar
• HaHLeeHBReactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucoseKidney Int Suppl200077S19S2510997686
   PubMed Web of Science ®Google Scholar
• SrivastavaSKRamanaKVBhatnagarARole of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic optionsEndocr Rev200526338039215814847
   PubMed Web of Science ®Google Scholar
• WilliamsonJRChangKFrangosMHyperglycemic pseudohypoxia and diabetic complicationsDiabetes19934268018138495803
   PubMed Web of Science ®Google Scholar
• LanaspaMAIshimotoTCicerchiCEndogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathyJ Am Soc Nephrol Epub5292014
   Web of Science ®Google Scholar
• SheetzMJKingGLMolecular understanding of hyperglycemia’s adverse effects for diabetic complicationsJAMA2002288202579258812444865
   PubMed Web of Science ®Google Scholar
• LanghamRGKellyDJGowRMIncreased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: relationship to long-term glycaemic controlDiabetologia200851466867418278479
   PubMed Web of Science ®Google Scholar
• NohHKingGLThe role of protein kinase C activation in diabetic nephropathyKidney Int Suppl2007106S49S5317653211
   PubMed Web of Science ®Google Scholar
• DerubertisFRCravenPAActivation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathyDiabetes1994431188262306
   PubMed Web of Science ®Google Scholar
• SakaiNWadaTFuruichiKInvolvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathyAm J Kidney Dis2005451546515696444
   PubMed Web of Science ®Google Scholar
• AdhikaryLChowFNikolic-PatersonDJAbnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathyDiabetologia20044771210122215232685
   PubMed Web of Science ®Google Scholar
• FiorinaPVerganiABassiRRole of podocyte B7-1 in diabetic nephropathyJ Am Soc Nephrol20142571415142924676639
   PubMed Web of Science ®Google Scholar
• MudaliarHPollockCKomalaMGChadbanSWuHPanchapakesanUThe role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubulesAm J Physiol Renal Physiol20133052F143F15423576640
   PubMed Web of Science ®Google Scholar
• SchmidHBoucherotAYasudaYModular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathyDiabetes200655112993300317065335
   PubMed Web of Science ®Google Scholar
• HofmannMASchiekoferSKanitzMInsufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetesDiabetes Care1998218131013169702439
   PubMed Web of Science ®Google Scholar
• SanchezAPSharmaKTranscription factors in the pathogenesis of diabetic nephropathyExpert Rev Mol Med200911e1319397838
   PubMed Web of Science ®Google Scholar
• LimAKTeschGHInflammation in diabetic nephropathyMediators Inflamm2012201214615422969168
   PubMed Web of Science ®Google Scholar
• ChowFYNikolic-PatersonDJMaFYOzolsERollinsBJTeschGHMonocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db miceDiabetologia200750247148017160673
   PubMed Web of Science ®Google Scholar
• LimAKMaFYNikolic-PatersonDJThomasMCHurstLATeschGHAntibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db miceDiabetologia20095281669167919466391
   PubMed Web of Science ®Google Scholar
• FurutaTSaitoTOotakaTThe role of macrophages in diabetic glomerulosclerosisAm J Kidney Dis19932154804858488815
   PubMed Web of Science ®Google Scholar
• NguyenDPingFMuWHillPAtkinsRCChadbanSJMacrophage accumulation in human progressive diabetic nephropathyNephrology (Carlton)200611322623116756636
   PubMed Web of Science ®Google Scholar
• BendingJJLobo-YeoAVerganiDVibertiGCProteinuria and activated T-lymphocytes in diabetic nephropathyDiabetes19883755075113258834
   PubMed Web of Science ®Google Scholar
• MoriyaRManivelJCMauerMJuxtaglomerular apparatus T-cell infiltration affects glomerular structure in Type 1 diabetic patientsDiabetologia2004471828814618232
   PubMed Web of Science ®Google Scholar
• LimAKMaFYNikolic-PatersonDJKitchingARThomasMCTeschGHLymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injuryDiabetologia20105381772178220422398
   PubMed Web of Science ®Google Scholar
• EllerKKirschAWolfAMPotential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathyDiabetes201160112954296221911743
   PubMed Web of Science ®Google Scholar
• XuJSuHLWangJHZhangCHRole of CD4+CD25+Foxp3+ regulatory T cells in type 2 diabetic nephropathyNan Fang Yi Ke Da Xue Xue Bao2009291137139 Chinese19218134
   PubMedGoogle Scholar
• IlanYMaronRTukpahAMInduction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob miceProc Natl Acad Sci U S A2010107219765977020445103
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• PerkovicVHeerspinkHLChalmersJIntensive glucose control improves kidney outcomes in patients with type 2 diabetesKidney Int201383351752323302714
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• GersteinHCMillerMEByingtonRPEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• Ismail-BeigiFCravenTBanerjiMAEffect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trialLancet2010376973941943020594588
   PubMed Web of Science ®Google Scholar
• KoGJKangYSHanSYPioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic ratsNephrol Dial Transplant20082392750276018388116
   PubMed Web of Science ®Google Scholar
• OhgaSShikataKYozaiKThiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activationAm J Physiol Renal Physiol20072924F1141F115017190910
   PubMed Web of Science ®Google Scholar
• ZhangHSahaJByunJRosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathyAm J Physiol Renal Physiol20082954F1071F108118667486
   PubMed Web of Science ®Google Scholar
• BakrisGLRuilopeLMMcMornSORosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuriaJ Hypertens200624102047205516957566
   PubMed Web of Science ®Google Scholar
• KoderaRShikataKTakatsukaTDipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetesBiochem Biophys Res Commun2014443382883324342619
   PubMed Web of Science ®Google Scholar
• MoriHOkadaYAraoTTanakaYSitagliptin improves albuminuria in patients with type 2 diabetes mellitusJ Diabetes Investig201453313319
   PubMed Web of Science ®Google Scholar
• FujitaHTaniaiHMurayamaHDPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathyEndocr J201461215916624225429
   PubMed Web of Science ®Google Scholar
• CherneyDZPerkinsBASoleymanlouNRenal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitusCirculation2014129558759724334175
   PubMed Web of Science ®Google Scholar
• VibertiGMogensenCEGroopLCPaulsJFEuropean Microalbuminuria Captopril Study GroupEffect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuriaJAMA199427142752798295285
   PubMed Web of Science ®Google Scholar
• The Microalbuminuria Captopril Study GroupCaptopril reduces the risk of nephropathy in IDDM patients with microalbuminuriaDiabetologia19963955875938739919
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGBainRPRohdeRDThe Collaborative Study GroupThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathyN Engl J Med199332920145614628413456
   PubMed Web of Science ®Google Scholar
• WilmerWAHebertLALewisEJRemission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril StudyAm J Kidney Dis199934230831410430979
   PubMed Web of Science ®Google Scholar
• HovindPRossingPTarnowLToftHParvingJParvingHHRemission of nephrotic-range albuminuria in type 1 diabetic patientsDiabetes Care200124111972197711679467
   PubMed Web of Science ®Google Scholar
• HovindPTarnowLRossingPCarstensenBParvingHHImproved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathyKidney Int20046631180118615327415
   PubMed Web of Science ®Google Scholar
• de GalanBEZoungasSChalmersJCognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trialDiabetologia200952112328233619688336
   PubMed Web of Science ®Google Scholar
• RuggenentiPFassiAIlievaAPPreventing microalbuminuria in type 2 diabetesN Engl J Med2004351191941195115516697
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• EijkelkampWBZhangZRemuzziGAlbuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialJ Am Soc Nephrol20071851540154617409317
   PubMed Web of Science ®Google Scholar
• HallerHItoSIzzoJLJrOlmesartan for the delay or prevention of microalbuminuria in type 2 diabetesN Engl J Med20113641090791721388309
   PubMed Web of Science ®Google Scholar
• BarnettAHBainSCBouterPAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med2004351191952196115516696
   PubMed Web of Science ®Google Scholar
• LvJPerkovicVFooteCVCraigMECraigJCStrippoliGFAntihypertensive agents for preventing diabetic kidney disease [review]Cochrane Database Syst Rev201212CD00413623235603
   PubMed Web of Science ®Google Scholar
• JacobsenPAndersenSRossingKJensenBRParvingHHDual blockade of the renin–angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathyKidney Int20036351874188012675866
   PubMed Web of Science ®Google Scholar
• JacobsenPAndersenSJensenBRParvingHHAdditive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathyJ Am Soc Nephrol200314499299912660333
   PubMed Web of Science ®Google Scholar
• MogensenCENeldamSTikkanenIRandomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) studyBMJ200032172741440144411110735
   PubMed Web of Science ®Google Scholar
• SongJHChaSHLeeHJEffect of low-dose dual blockade of renin–angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney diseaseNephrol Dial Transplant200621368368916330466
   PubMed Web of Science ®Google Scholar
• MannJFAndersonCGaoPDual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trialJ Hypertens201331241442123249829
   PubMed Web of Science ®Google Scholar
• FriedLFEmanueleNZhangJHCombined angiotensin inhibition for the treatment of diabetic nephropathyN Engl J Med2013369201892190324206457
   PubMed Web of Science ®Google Scholar
• WolfGRenal injury due to renin–angiotensin–aldosterone system activation of the transforming growth factor-beta pathwayKidney Int200670111914191916985515
   PubMed Web of Science ®Google Scholar
• HuangWXuCKahngKWNobleNABorderWAHuangYAldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cellsAm J Physiol Renal Physiol20082946F1287F129518367662
   PubMed Web of Science ®Google Scholar
• SchjoedtKJRossingKJuhlTRBeneficial impact of spironolactone in diabetic nephropathyKidney Int20056862829283616316360
   PubMed Web of Science ®Google Scholar
• RossingKSchjoedtKJSmidtUMBoomsmaFParvingHHBeneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over studyDiabetes Care20052892106211216123474
   PubMed Web of Science ®Google Scholar
• HanSYKimCHKimHSSpironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic ratsJ Am Soc Nephrol20061751362137216571782
   PubMed Web of Science ®Google Scholar
• EpsteinMWilliamsGHWeinbergerMSelective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetesClin J Am Soc Nephrol20061594095117699311
   PubMed Web of Science ®Google Scholar
• BakrisGLCopleyJBVicknairNSadlerRLeurgansSCalcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathyKidney Int1996505164116508914031
   PubMed Web of Science ®Google Scholar
• BakrisGLBarnhillBWSadlerRTreatment of arterial hypertension in diabetic humans: importance of therapeutic selectionKidney Int19924149129191325010
   PubMed Web of Science ®Google Scholar
• BakrisGLWeirMRDeQuattroVMcMahonFGEffects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathyKidney Int1998544128312899767545
   PubMed Web of Science ®Google Scholar
• RuggenentiPFassiAIlievaAEffects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trialJ Hypertens201129220721621243736
   PubMed Web of Science ®Google Scholar
• VibertiGWheeldonNMMicroalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effectCirculation2002106667267812163426
   PubMed Web of Science ®Google Scholar
• HerlitzHHarrisKRislerTThe effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros StudyNephrol Dial Transplant200116112158216511682661
   PubMed Web of Science ®Google Scholar
• RuggenentiPPernaALorigaGBlood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trialLancet2005365946393994615766995
   PubMed Web of Science ®Google Scholar
• JamesPAOparilSCarterBL2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)JAMA2014311550752024352797
   PubMed Web of Science ®Google Scholar
• ManciaGFagardRNarkiewiczK2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20133171281135723817082
   PubMed Web of Science ®Google Scholar
• PilmoreHDograGRobertsMCardiovascular disease in patients with chronic kidney diseaseNephrology (Carlton)201419131023927055
   PubMed Web of Science ®Google Scholar
• National Kidney FoundationKDOQI clinical practice guideline for diabetes and CKD: 2012 updateAm J Kidney Dis201260585088623067652
   PubMed Web of Science ®Google Scholar
• RuzickaMQuinnRRMcFarlanePCanadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKDAm J Kidney Dis201463686988724725980
   PubMed Web of Science ®Google Scholar
• SacksFMHermansMPFiorettoPAssociation between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case–control study in 13 countriesCirculation20141299999100824352521
   PubMed Web of Science ®Google Scholar
• KrolewskiASWarramJHChristliebARHypercholesterolemia – a determinant of renal function loss and deaths in IDDM patients with nephropathyKidney Int Suppl199445S1251318158881
   PubMed Web of Science ®Google Scholar
• IshibashiYYamagishiSMatsuiTPravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) levelMetabolism20126181067107222386936
   PubMed Web of Science ®Google Scholar
• GaoPWuXShuiHJiaRFluvastatin inhibits high glucose-induced nuclear factor kappa B activation in renal tubular epithelial cellsJ Nephrol201326228929622641573
   PubMed Web of Science ®Google Scholar
• TobaHMitaniTTakahashiTInhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetesClin Exp Pharmacol Physiol201037111064107020678154
   PubMed Web of Science ®Google Scholar
• TonoloGVelussiMBroccoESimvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetesKidney Int200670117718616710349
   PubMed Web of Science ®Google Scholar
• AbeMMaruyamaNOkadaKMatsumotoSMatsumotoKSomaMEffects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathyJ Atheroscler Thromb201118111018102821921413
   PubMed Web of Science ®Google Scholar
• CollinsRArmitageJParishSSleighPPetoRHeart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialLancet200336193742005201612814710
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNEffects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)Am J Kidney Dis200954581081919540640
   PubMed Web of Science ®Google Scholar
• GersteinHCMannJFYiQAlbuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individualsJAMA2001286442142611466120
   PubMed Web of Science ®Google Scholar
• FicocielloLHRosolowskyETNiewczasMAHigh-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-upDiabetes Care20103361337134320332356
   PubMed Web of Science ®Google Scholar
• JalalDIRivardCJJohnsonRJSerum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes studyNephrol Dial Transplant20102561865186920064950
   PubMed Web of Science ®Google Scholar
• HovindPRossingPTarnowLJohnsonRJParvingHHSerum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort studyDiabetes20095871668167119411615
   PubMed Web of Science ®Google Scholar
• MiaoYOttenbrosSALavermanGDEffect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialHypertension20115812721632472
   PubMed Web of Science ®Google Scholar
• KimSMChoiYWSeokHYReducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathyNephron Exp Nephrol20121213–4e109e12123307286
   PubMedGoogle Scholar
• KosugiTNakayamaTHeinigMEffect of lowering uric acid on renal disease in the type 2 diabetic db/db miceAm J Physiol Renal Physiol20092972F481F48819458127
   PubMed Web of Science ®Google Scholar
• DoganAYarliogluesMKayaMGEffect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patientsBlood Press201120318218721133824
   PubMed Web of Science ®Google Scholar
• ButlerRMorrisADBelchJJHillAStruthersADAllopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertensionHypertension200035374675110720589
   PubMed Web of Science ®Google Scholar
• TalaatKMel-SheikhARThe effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney diseaseAm J Nephrol200727543544017622758
   PubMed Web of Science ®Google Scholar
• MaahsDMCaramoriLCherneyDZUric acid lowering to prevent kidney function loss in diabetes: the Preventing Early Renal Function Loss (PERL) allopurinol studyCurr Diab Rep201313455055923649945
   PubMed Web of Science ®Google Scholar
• ZhangZZhangYNingGDebDKKongJLiYCCombination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increaseProc Natl Acad Sci U S A200810541158961590118838678
   PubMed Web of Science ®Google Scholar
• WangYDebDKZhangZVitamin D receptor signaling in podocytes protects against diabetic nephropathyJ Am Soc Nephrol201223121977198623123403
   PubMed Web of Science ®Google Scholar
• XiongMGongJLiuYXiangRTanXLoss of vitamin D receptor in chronic kidney disease: a potential mechanism linking inflammation to epithelial-to-mesenchymal transitionAm J Physiol Renal Physiol20123037F1107F111522791341
   PubMed Web of Science ®Google Scholar
• NakaiKFujiiHKonoKVitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic ratsAm J Hypertens201427458659524025724
   PubMed Web of Science ®Google Scholar
• Fernandez-JuarezGLunoJBarrioV25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin–angiotensin systemClin J Am Soc Nephrol20138111870187624135218
   PubMed Web of Science ®Google Scholar
• de ZeeuwDAgarwalRAmdahlMSelective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialLancet201037697521543155121055801
   PubMed Web of Science ®Google Scholar
• BrownJMSecinaroKWilliamsJSVaidyaAEvaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D studyBMC Endocr Disord20131313323971740
   PubMed Web of Science ®Google Scholar
• MakuraCBNirantharakumarKGirlingAJSaravananPNarendranPEffects of physical activity on the development and progression of microvascular complications in type 1 diabetes: retrospective analysis of the DCCT studyBMC Endocr Disord20131313724083407
   PubMed Web of Science ®Google Scholar
• WingRRBolinPBrancatiFLCardiovascular effects of intensive lifestyle intervention in type 2 diabetesN Engl J Med2013369214515423796131
   PubMed Web of Science ®Google Scholar
• NezuUKamiyamaHKondoYSakumaMMorimotoTUedaSEffect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trialsBMJ Open201335e002934
   Web of Science ®Google Scholar
• AndersonJWBeneficial effects of soy protein consumption for renal functionAsia Pac J Clin Nutr200817Suppl 132432818296369
   PubMed Web of Science ®Google Scholar
• KwakernaakAJKrikkenJABinnenmarsSHEffects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trialLancet Diabetes Endocrinol20142538539524795252
   PubMed Web of Science ®Google Scholar
• HoulihanCAAllenTJBaxterALA low-sodium diet potentiates the effects of losartan in type 2 diabetesDiabetes Care200225466367111919122
   PubMed Web of Science ®Google Scholar
• PedersenOGaedePIntensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 studyMetabolism2003528 Suppl 1192312939735
   PubMed Web of Science ®Google Scholar
• BohmanSOTydenGWilczekHPrevention of kidney graft diabetic nephropathy by pancreas transplantation in manDiabetes19853433063083918902
   PubMed Web of Science ®Google Scholar
• BilousRWMauerSMSutherlandDENajarianJSGoetzFCSteffesMWThe effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetesN Engl J Med1989321280852659996
   PubMed Web of Science ®Google Scholar
• FiorettoPSteffesMWSutherlandDEGoetzFCMauerMReversal of lesions of diabetic nephropathy after pancreas transplantationN Engl J Med1998339269759654536
   PubMed Web of Science ®Google Scholar
• FiorettoPSutherlandDENajafianBMauerMRemodeling of renal interstitial and tubular lesions in pancreas transplant recipientsKidney Int200669590791216518350
   PubMed Web of Science ®Google Scholar
• KellyDJZhangYMoeGNaikGGilbertREAliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in ratsDiabetologia200750112398240417828524
   PubMed Web of Science ®Google Scholar
• PerssonFRossingPSchjoedtKJTime course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetesKidney Int200873121419142518337712
   PubMed Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBLewisEJHollenbergNKAliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med2008358232433244618525041
   PubMed Web of Science ®Google Scholar
• ParvingHHBrennerBMMcMurrayJJCardiorenal end points in a trial of aliskiren for type 2 diabetesN Engl J Med2012367232204221323121378
   PubMed Web of Science ®Google Scholar
• SasserJMSullivanJCHobbsJLEndothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanismJ Am Soc Nephrol200718114315417167119
   PubMed Web of Science ®Google Scholar
• GagliardiniECornaDZojaCUnlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetesAm J Physiol Renal Physiol20092975F1448F145619675181
   PubMed Web of Science ®Google Scholar
• MannJFGreenDJamersonKAvosentan for overt diabetic nephropathyJ Am Soc Nephrol201021352753520167702
   PubMed Web of Science ®Google Scholar
• WenzelRRLittkeTKuranoffSAvosentan reduces albumin excretion in diabetics with macroalbuminuriaJ Am Soc Nephrol200920365566419144760
   PubMed Web of Science ®Google Scholar
• de ZeeuwDCollBAndressDThe endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyJ Am Soc Nephrol20142551083109324722445
   PubMed Web of Science ®Google Scholar
• SidhartaPNWagnerFDBohnemeierHPharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patientsClin Pharmacol Ther200680324625616952491
   PubMed Web of Science ®Google Scholar
• VogtLChiurchiuCChadha-BorehamHEffect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathyHypertension20105551206120920231521
   PubMed Web of Science ®Google Scholar
• SchaferSLinzWVollertHThe vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathyDiabetologia20044719810314618238
   PubMed Web of Science ®Google Scholar
• DavisBJJohnstonCIBurrellLMRenoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathyDiabetologia200346796197112838387
   PubMed Web of Science ®Google Scholar
• KoyaDHanedaMNakagawaHAmelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetesFASEB J200014343944710698958
   PubMed Web of Science ®Google Scholar
• WuYWuGQiXProtein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic ratsJ Pharmacol Sci2006101433534316891764
   PubMed Web of Science ®Google Scholar
• GilbertREKimSATuttleKREffect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetesDiabetes Care200730499599617229944
   PubMed Web of Science ®Google Scholar
• TuttleKRBakrisGLTotoRDMcGillJBHuKAndersonPWThe effect of ruboxistaurin on nephropathy in type 2 diabetesDiabetes Care200528112686269016249540
   PubMed Web of Science ®Google Scholar
• TuttleKRMcGillJBHaneyDJLinTEAndersonPWKidney outcomes in long-term studies of ruboxistaurin for diabetic eye diseaseClin J Am Soc Nephrol20072463163617699475
   PubMed Web of Science ®Google Scholar
• ItagakiIShimizuKKamanakaYThe effect of an aldose reductase inhibitor (epalrestat) on diabetic nephropathy in ratsDiabetes Res Clin Pract19942531471547851268
   PubMed Web of Science ®Google Scholar
• DonnellySMZhouXPHuangJTWhitesideCIPrevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic ratBiochem Cell Biol19967433553628883841
   PubMed Web of Science ®Google Scholar
• IsoKTadaHKubokiKInokuchiTLong-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in type 2 diabetic patientsJ Diabetes Complications200115524124411522497
   PubMed Web of Science ®Google Scholar
• HottaNKawamoriRFukudaMShigetaYLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathyDiabet Med201229121529153322507139
   PubMed Web of Science ®Google Scholar
• RanganathanSKrempfMFerailleECharbonnelBShort term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathyDiabete Metab19931922572618339858
   PubMed Web of Science ®Google Scholar
• WangXYanLChenWXuLZhangXThe renal protective effects of cilostazol on suppressing pathogenic thrombospondin-1 and transforming growth factor-beta expression in streptozotocin-induced diabetic ratsJ Int Med Res200937114515319215684
   PubMed Web of Science ®Google Scholar
• TohmaTShimabukuroMOshiroYYamakawaMShimajiriYTakasuNCilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty ratMetabolism200453111405141015536593
   PubMed Web of Science ®Google Scholar
• WatanabeJSakoYUmedaFNawataHEffects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patientsDiabetes Res Clin Pract199322153598137717
   PubMed Web of Science ®Google Scholar
• JiaoXMJiaoXJZhangXGCilostazol reduces microalbuminuria in type 2 diabetic nephropathyChin Med J (Engl)2013126224395439624238537
   PubMed Web of Science ®Google Scholar
• ShanDWuHMYuanQYLiJZhouRLLiuGJPentoxifylline for diabetic kidney disease [review]Cochrane Database Syst Rev20122CD00680022336824
   PubMed Web of Science ®Google Scholar
• RoozbehJBanihashemiMAGhezlouMCaptopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathyRen Fail201032217217820199178
   PubMed Web of Science ®Google Scholar
• OliaeiFHushmandSKhafriSBaradaranMEfficacy of pentoxifylline for reduction of proteinuria in type II diabetic patientsCaspian J Intern Med20112430931324551437
   PubMedGoogle Scholar
• GhorbaniAOmidvarBBeladi-MousaviSSLakEVaziriSThe effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trialNefrologia201232679079623169362
   PubMed Web of Science ®Google Scholar
• Navarro-GonzalezJFMurosMMora-FernandezCHerreraHMenesesBGarciaJPentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal resultsJ Diabetes Complications201125531431921144773
   PubMed Web of Science ®Google Scholar
• ThornalleyPJUse of aminoguanidine (pimagedine) to prevent the formation of advanced glycation endproductsArch Biochem Biophys20034191314014568006
   PubMed Web of Science ®Google Scholar
• Soulis-LiparotaTCooperMPapazoglouDClarkeBJerumsGRetardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic ratDiabetes19914010132813341834497
   PubMed Web of Science ®Google Scholar
• BoltonWKCattranDCWilliamsMERandomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyAm J Nephrol2004241324014685005
   PubMed Web of Science ®Google Scholar
• WilliamsMEBoltonWKKhalifahRGDegenhardtTPSchotzingerRJMcGillJBEffects of pyridoxamine in combined Phase II studies of patients with type 1 and type 2 diabetes and overt nephropathyAm J Nephrol200727660561417823506
   PubMed Web of Science ®Google Scholar
• LewisEJGreeneTSpitalewizSPyridorin in type 2 diabetic nephropathyJ Am Soc Nephrol201223113113622034637
   PubMed Web of Science ®Google Scholar
• KennedyLSolanoMPMeneghiniLLoMCohenMPAnti-glycation and anti-albuminuric effects of GLY-230 in human diabetesAm J Nephrol201031211011619923796
   PubMed Web of Science ®Google Scholar
• RuizSPergolaPEZagerRAVaziriNDTargeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney diseaseKidney Int20138361029104123325084
   PubMed Web of Science ®Google Scholar
• PergolaPERaskinPTotoRDBardoxolone methyl and kidney function in CKD with type 2 diabetesN Engl J Med2011365432733621699484
   PubMed Web of Science ®Google Scholar
• de ZeeuwDAkizawaTAudhyaPBardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseN Engl J Med2013369262492250324206459
   PubMed Web of Science ®Google Scholar
• ZojaCCornaDNavaVAnalogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effectsAm J Physiol Renal Physiol20133046F808F81923136004
   PubMed Web of Science ®Google Scholar
• CiszewiczMPolubinskaAAntoniewiczASuminska-JasinskaKBreborowiczASulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicityTransl Res2009153311812319218094
   PubMed Web of Science ®Google Scholar
• MasolaVZazaGGambaroGSulodexide and glycosaminoglycans in the progression of renal diseaseNephrol Dial Transplant201429Suppl 1i74i7924493873
   PubMed Web of Science ®Google Scholar
• GambaroGKinalskaIOksaAOral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the DiNAS randomized trialJ Am Soc Nephrol20021361615162512039991
   PubMed Web of Science ®Google Scholar
• LewisEJLewisJBGreeneTSulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trialAm J Kidney Dis201158572973621872376
   PubMed Web of Science ®Google Scholar
• PackhamDKWolfeRReutensATSulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathyJ Am Soc Nephrol201223112313022034636
   PubMed Web of Science ®Google Scholar
• RamachandraRaoSPZhuYRavasiTPirfenidone is renoprotective in diabetic kidney diseaseJ Am Soc Nephrol20092081765177519578007
   PubMed Web of Science ®Google Scholar
• KaSMYehYCHuangXRKidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in miceDiabetologia201255250951922086159
   PubMed Web of Science ®Google Scholar
• ZhangZWuFZhengFLiHAdenovirus-mediated decorin gene transfection has therapeutic effects in a streptozocin-induced diabetic rat modelNephron Exp Nephrol20101161e11e2120502052
   PubMedGoogle Scholar
• FlaquerMFranquesaMVidalAHepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetesDiabetologia20125572059206822460762
   PubMed Web of Science ®Google Scholar
• KosugiTNakayamaTLiQSoluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic miceAm J Physiol Renal Physiol20102983F609F61620015944
   PubMed Web of Science ®Google Scholar
• LiDWangNZhangLMesenchymal stem cells protect podocytes from apoptosis induced by high glucose via secretion of epithelial growth factorStem Cell Res Ther20134510324004644
   PubMed Web of Science ®Google Scholar
• ZhangYYuenDAAdvaniAEarly-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetesDiabetes20126182114212522596053
   PubMed Web of Science ®Google Scholar
• SabbisettiVSWaikarSSAntoineDJBlood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetesJ Am Soc Nephrol Epub652014
   Web of Science ®Google Scholar
• NielsenSEAndersenSZdunekDHessGParvingHHRossingPTubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathyKidney Int201179101113111821270761
   PubMed Web of Science ®Google Scholar
• ConwayBRManoharanDJenksSMeasuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factorsKidney Int201282781281822718188
   PubMed Web of Science ®Google Scholar
• LacquanitiADonatoVPintaudiB“Normoalbuminuric” diabetic nephropathy: tubular damage and NGALActa Diabetol201350693594223754672
   PubMed Web of Science ®Google Scholar
• ChouKMLeeCCChenCHSunCYClinical value of NGAL, L-FABP, and albuminuria in predicting GFR decline in type 2 diabetes mellitus patientsPLoS One201381e5486323349979
   PubMed Web of Science ®Google Scholar
• PanduruNMForsblomCSaraheimoMUrinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetesDiabetes Care20133672077208323378622
   PubMed Web of Science ®Google Scholar
• NielsenSESugayaTHovindPBabaTParvingHHRossingPUrinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patientsDiabetes Care20103361320132420185732
   PubMed Web of Science ®Google Scholar
• ArakiSHanedaMKoyaDPredictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathyDiabetes Care20133651248125323223350
   PubMed Web of Science ®Google Scholar
• Kamijo-IkemoriASugayaTYasudaTClinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patientsDiabetes Care201134369169621273494
   PubMed Web of Science ®Google Scholar
• KimSSSongSHKimIJUrinary cystatin C and tubular proteinuria predict progression of diabetic nephropathyDiabetes Care201336365666123093662
   PubMed Web of Science ®Google Scholar
• FallahzadehMKDormaneshBSaghebMMEffect of addition of silymarin to renin–angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trialAm J Kidney Dis201260689690322770926
   PubMed Web of Science ®Google Scholar
• KhanMISiddiqueKUAshfaqFAliWReddyHDMishraAEffect of high-dose zinc supplementation with oral hypoglycemic agents on glycemic control and inflammation in type-2 diabetic nephropathy patientsJ Nat Sci Biol Med20134233634024082728
   PubMedGoogle Scholar
• ParhamMAminiMAminorroayaAHeidarianEEffect of zinc supplementation on microalbuminuria in patients with type 2 diabetes: a double blind, randomized, placebo-controlled, cross-over trialRev Diabet Stud20085210210918795212
   PubMedGoogle Scholar
• KhajehdehiPPakfetratMJavidniaKOral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled studyScand J Urol Nephrol201145536537021627399
   PubMed Web of Science ®Google Scholar
• RossingPHansenBVNielsenFSMyrupBHolmerGParvingHHFish oil in diabetic nephropathyDiabetes Care19961911121412198908382
   PubMed Web of Science ®Google Scholar
• LeeRHSeoMJRegerRLMultipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid miceProc Natl Acad Sci U S A200610346174381744317088535
   PubMed Web of Science ®Google Scholar
• EzquerFEEzquerMEParrauDBCarpioDYanezAJCongetPASystemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic miceBiol Blood Marrow Transplant200814663164018489988
   PubMed Web of Science ®Google Scholar
• EzquerFEzquerMSimonVEndovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic miceBiol Blood Marrow Transplant200915111354136519822294
   PubMed Web of Science ®Google Scholar
• ZhouHTianHMLongYMesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in ratsChin Med J (Engl)2009122212573257919951572
   PubMed Web of Science ®Google Scholar
• ParkJHParkJHwangSHHanHHaHDelayed treatment with human umbilical cord blood-derived stem cells attenuates diabetic renal injuryTransplant Proc20124441123112622564642
   PubMed Web of Science ®Google Scholar
• ParkJHHwangIHwangSHHanHHaHHuman umbilical cord blood-derived mesenchymal stem cells prevent diabetic renal injury through paracrine actionDiabetes Res Clin Pract201298346547323026513
   PubMed Web of Science ®Google Scholar
• FangYTianXBaiSAutologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines, and the p38 MAPK signaling pathwayInt J Mol Med2012301859222552764
   PubMed Web of Science ®Google Scholar
• WangSLiYZhaoJZhangJHuangYMesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat modelBiol Blood Marrow Transplant201319453854623295166
   PubMed Web of Science ®Google Scholar
• LvSSLiuGWangJPMesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltrationInt Immunopharmacol201317227528223791972
   PubMed Web of Science ®Google Scholar
• ZhangYYeCWangGKidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy ratsBiomed Res Int2013201352636723762850
   PubMed Web of Science ®Google Scholar
• ZhangLLiKLiuXRepeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in ratsStem Cells Dev201322233074308623844841
   PubMed Web of Science ®Google Scholar
• Abdel AzizMTWassefMAAhmedHHThe role of bone marrow derived-mesenchymal stem cells in attenuation of kidney function in rats with diabetic nephropathyDiabetol Metab Syndr2014613424606996
   PubMed Web of Science ®Google Scholar